U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07626034) titled 'A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398' on May 21.
Brief Summary: This is an open label study in 2 cohorts of healthy volunteers and 1 cohort of patients with Schizophrenia, designed to evaluate the Dopamine D2 and D3 Receptor Occupancy by SIPI6398 at various doses and timepoints.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Schizophrenia Disorder
Intervention:
DRUG: SIPI6398 Tablets
SIPI6398 Tablets will be administered orally once daily for 7 consecutive days to healthy volunteers or for 8 consecutive days to patients with schizophrenia....